source
- Summit Therapeutics' ivonescimab shows improved survival trend in extended follow-up, easing investor doubtsA new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…
- FDA moves to reverse policies of former commissioner Marty MakaryThe Trump administration is actively rolling back decisions made under former FDA commissioner Marty Makary. As the White House weighs a new nominee for the agency, officials have begun revisiting…